Cathie Wood’s Ark keeps selling one stock once again

Cathie Wood, caput of Ark Investment Management, is known for making bold, conviction-driven bets, but she’s conscionable arsenic speedy to trim positions erstwhile the strategy shifts. That signifier is playing retired again this week.

ARK Investment Management has continued selling shares of Strata Critical Medical (NASDAQ: SRTA), extending a multi-day streak of accordant reductions. On April 13, the steadfast offloaded 182,767 shares worthy astir $738,378 crossed its ARKQ and ARKX exchange-traded funds.

This wasn’t a one-off move. The steadfast has been trimming SRTA daily, including a merchantability of 75,389 shares connected April 10. That dependable signifier suggests thing much deliberate is happening down the scenes.

So wherefore is Ark pulling backmost from a institution that’s inactive posting beardown growth?

Ark’s caller commercialized enactment points to a wide trend. A systematic simplification successful its vulnerability to Strata Critical Medical.

The April 13 merchantability included 144,198 shares sold done the ARK Autonomous Technology & Robotics ETF, and 38,569 shares sold done the ARK Space Exploration & Innovation ETF.

Related: Cathie Wood buys $6.9 cardinal of surging tech stock

Notably, Ark reported nary large caller income oregon buys successful that update, making SRTA the standout determination of the day.

For investors who travel Ark’s regular trades closely, this benignant of repeated selling often signals a broader portfolio displacement alternatively than short-term profit-taking.

What makes this determination basal retired is that Strata Critical Medical’s fundamentals haven’t weakened. In fact, they’ve improved significantly.

March 03, 2026, Strata delivered a standout 4th quarter, backed by beardown growth, improving margins, and raised guardant guidance.

• Revenue: $66.8 cardinal (+83.5% YoY)

• Logistics revenue: $49.2 cardinal (+35.3% YoY)

• Clinical revenue: $17.6 cardinal (boosted by Keystone acquisition)

• Gross profit: $14.4 cardinal (+90% YoY)

• Gross margin: 21.6% (up from 20.8%)

• Adjusted EBITDA: $7.0 cardinal (vs. $1.1M past year)

• Net loss: narrowed to $5.4 cardinal (from $7.4M)

Beyond growth, profitability trends are improving, adjacent arsenic the institution continues to invest:

• Operating currency flow: $8.3 million

• Free currency flow: $8.7 million

• Cash position: $61.2 cardinal astatine year-end

Looking ahead, absorption is raising expectations:

• 2026 gross guidance: $260–$275 cardinal (raised)

• Adjusted EBITDA: $29–$33 cardinal (raised)

• Free currency travel (ex-aircraft): $15–$22 million

Co-CEO and COO Will Heyburn pointed to continued momentum, noting the institution is inactive exceeding its maturation targets.